▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / ITRMF

ITRMF — Iterum Therapeutics plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1659323 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 390,000 370,000 -7,731,000 -8,979,000 32,503,000 11,002,000 39,884,000
Jun 2025 0 -345,000 -5,529,000 -6,509,000 34,014,000 13,026,000 37,901,000
Mar 2025 0 -342,000 -3,710,000 -4,891,000 32,975,000 12,652,000 35,529,000
Dec 2024 0 — -3,670,000 -6,582,000 44,595,000 24,125,000 48,676,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-19,514,000
Investing CF
$1,086,000
Financing CF
$16,041,000
CapEx
$-14,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-506,451,000
Inventory
$1,149,000
Receivables
$546,000
ST Investments
$0
EBIT TTM
$-24,520,000
Pretax Income TTM
$-26,685,000
Interest Exp TTM
$2,165,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$390,000
EBITDA
$-19,324,000
Free Cash Flow
$-13,851,125
Enterprise Value
$25,636,322
Total Cash
$11,002,000
Total Debt
$33,735,000
Shares Out
53,291,578
Trailing EPS
$-0.72
Book Value
$-0.15
ROE
—
ROA
-53.3%
Div Yield
—

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 0 -18,696,000 -24,774,000 44,595,000 48,676,000 — -26,770,000
Dec 2023 0 -47,468,000 -38,371,000 26,259,000 32,662,000 — -39,330,000
Dec 2022 0 -30,383,000 -44,434,000 66,833,000 38,834,000 — -18,473,000

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $949.47B $1064.74 —
JNJ JOHNSON & JOHNSON $554.09B $230.18 —
ABBV AbbVie Inc. $376.54B $213.12 —
MRK Merck & Co., Inc. $295.69B $119.72 —
AZN ASTRAZENECA PLC $290.30B $187.19 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →